-
Suzhou Ribo Life Science Receives EU Approval for Phase II Trial of RBD5044
•
Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB have announced that their novel siRNA drug, RBD5044, has received approval to commence Phase II clinical trials in the European Union. This represents a significant step forward in the development of RNA interference therapies targeting lipid metabolism. RBD5044:…
-
Boehringer Ingelheim Partners with Suzhou Ribo Life Science to Develop siRNA Therapies for NASH/MASH
•
Boehringer Ingelheim (BI), a Germany-headquartered pharmaceutical company, has entered into a collaboration agreement with Suzhou Ribo Life Science Co., Ltd, a Chinese biotechnology firm, to co-develop small interfering RNA (siRNA) drugs for the treatment of non-alcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). This strategic partnership aims to leverage Ribo’s proprietary RIBO-GalSTAR…
-
Suzhou Ribo Life Science Strikes Deal with Qilu Pharmaceutical for PCSK9 siRNA Drug
•
Suzhou Ribo Life Science Co., Ltd, a specialist in small interfering RNA (siRNA) drugs based in China, has entered into a licensing agreement with Qilu Pharmaceutical, granting the company clinical development, manufacturing, and commercialization rights to its PCSK9 siRNA drug RBD7022 in Greater China, which includes mainland China, Hong Kong,…
